AUM Biosciences invited to attend the China Focus@JPM Week event, held in San Francisco on 6 January 2019

San Francisco, CA, 6 January 2019

AUM has been invited to attend the China Focus@JPM Week event on 6th January 2019, taking place in San Francisco, CA. The event brings together investors and pharma leaders from China and healthcare innovators to inspire, educate and foster cross-border investment and collaboration in leading biopharma innovations from around the world.

Since the recent reform of China’s drug approval process, clinical trials and new drug approval in China has speeded up. In 2017 alone, 34 pharma products and 5 biotech products were approved, making a record high in the history.

There is much to look forward to with China’s new reforms and we are delighted to explore these opportunities further.

Read more here.

For more information, please contact

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit